Solid Biosciences was expected to ride gene therapy’s wave of recent momentum to an IPO this week. But the offering, possibly for more than $130 million, did not go off as planned last night, and the company revealed this morning that its most advanced drug candidate has been under FDA scrutiny since mid-November. The gene […]